Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	12.62	13.16	63.46	16.46	5.15
Short-Term Investments	14.53	29.14	5.99	27.8	72.83
Cash & Cash Equivalents	27.15	42.3	69.45	44.26	77.98
Cash Growth	-35.82%	-39.09%	56.92%	-43.24%	-31.95%
Receivables	0.03	0.59	0.51	0	0
Other Current Assets	0.78	0.77	1.35	1.08	1.36
Total Current Assets	27.96	43.66	71.31	45.34	79.34
Property, Plant & Equipment	1.39	2.57	3.64	2.55	3.79
Long-Term Investments	16.12	21.88	34.27	37.23	0
Other Long-Term Assets	0.09	0.13	0.24	0.41	0.51
Total Long-Term Assets	17.6	24.58	38.14	40.19	4.3
Total Assets	45.55	68.24	109.46	85.53	83.65
Accounts Payable	1.53	1.98	1.57	3.47	2.45
Current Debt	1.37	1.23	1.05	1.08	0.88
Other Current Liabilities	3.97	7.55	7.08	7.6	6.9
Total Current Liabilities	6.87	10.75	9.69	12.15	10.23
Long-Term Debt	0	1.37	2.6	1.23	2.31
Total Long-Term Liabilities	0	1.37	2.6	1.23	2.31
Total Liabilities	6.87	12.13	12.29	13.38	12.54
Total Debt	1.37	2.6	3.65	2.31	3.19
Debt Growth	-47.17%	-28.68%	57.88%	-27.54%	-
Retained Earnings	-334.72	-307.69	-266.38	-223.14	-217.15
Comprehensive Income	-0.97	-0.56	1.87	0	0.03
Shareholders' Equity	38.68	56.12	97.16	72.15	71.11
Net Cash / Debt	25.78	39.7	65.8	41.95	74.79
Net Cash / Debt Growth	-35.08%	-39.67%	56.87%	-43.91%	-34.73%
Net Cash Per Share	0.54	0.85	1.57	1.42	2.55
Working Capital	21.09	32.91	61.62	33.19	69.12
Book Value Per Share	0.81	1.21	2.32	2.45	2.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).